Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford Professor of Tropical Medicine Kevin Marsh has won the Al-Sumait Prize for Health for his contributions to health in Africa.

Professor Marsh is a principal investigator at the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya, as well as senior adviser to the African Academy of Sciences. His award recognises his sustained efforts to control and eradicate malaria, which impacts the health of tens of millions of African children.

Professor Marsh said: 'I am honoured to have been awarded the Al-Sumait prize in recognition of work carried out with many colleagues in Africa and in Oxford.  The prize will be used to support the work of the African Academy of Sciences and the Africa Oxford Initiative, a new platform which brings together academics from across the University and from many African institutions to build equitable collaborations in all academic disciplines.'

Read more

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.